SAB Biotherapeutics, Inc.SABSNASDAQ

Revenue (LTM)

-100.0% YoY

Net Income (LTM)

$13M

+138.9% YoY

Free Cash Flow

$-46M

Revenue CAGR (5Y)

—

Marginsdeclining

FCF($0.0B)

Now profitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	61	24↓60.7%	2↓90.6%	1↓40.9%	0
Gross Profit	59	21↓65.2%	-2↓107.3%	-3↓130.4%	-3↑11.2%
Operating Income	-13	-29↓115.9%	-38↓31.7%	-43↓12.7%	-49↓14.1%
Net Income	-17	-19↓9.3%	-42↓125.1%	-34↑19.2%	13↑138.9%
EBITDA	-15	-15↑0.5%	-38↓152.2%	-29↑24.0%	-46↓58.2%
EPS Diluted	-6.30	-4.31↑31.6%	-7.64↓77.3%	-3.68↑51.8%	-0.79↑78.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	33	15↓54.7%	57↑275.9%	9↓84.3%	11↑18.0%
Total Current Assets	50	22↓56.0%	59↑166.6%	24↓59.6%	101↑324.7%
Total Assets	81	51↓37.3%	84↑64.9%	44↓47.3%	173↑291.0%
Total Current Liabilities	26	15↓43.3%	11↓27.9%	8↓26.2%	11↑33.9%
Total Liabilities	43	20↓53.4%	27↑34.2%	18↓31.6%	21↑17.0%
Total Equity	39	31↓19.4%	57↑84.5%	26↓54.7%	151↑483.4%
Total Debt	9	6↓30.4%	6↓0.4%	5↓21.0%	6↑27.5%
Net Debt	-25	-9↑63.1%	-51↓455.6%	-4↑91.7%	-5↓7.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	2	-23↓1280.7%	-25↓7.1%	-34↓36.5%	-45↓30.6%
Capital Expenditure	-11	-2↑80.2%	-0↑90.9%	-0↓71.1%	-1↓176.7%
Free Cash Flow	-9	-26↓186.1%	-25↑1.2%	-35↓36.8%	-46↓32.0%
Stock-Based Comp	2	3↑15.5%	2↓9.4%	3↑21.4%	5↑77.1%
Net Change in Cash	27	-24↓191.0%	42↑269.5%	-48↓214.8%	2↑103.4%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance